Internal restructuring: Wyeth told managers about 10 percent of its 50,000 employees worldwide might lose their jobs by 2011 under a sweeping reorganization dubbed "Project Impact.": United States of America

2005

-1200

Closure/Bankruptcy: United States of America

Les Echos

2002

52762

2001

52289

2000

48036

1999

-3000

1999

-700

Reuters

1998

60523

» More restructuring at Wyeth
» Layoff plans and labour conditions in 2007

year

employees

social impact : country

source

8 informations, access to subscribers

» More restructuring at Wyeth
» Layoff plans and labour conditions in 2007

year

country : consequences

source

2007

United States of America : Wyeth was condemned to pay 134 million dollars to three patients who developed a breast cancer because of their hormonal treatment Premanal and Prempro.

Les Echos

2005

United States of America : Wyeth a versé 14 milliards de dollars aux patients qui ont pris son coupe-faim Redux, retiré du marché en 1997. Wyeth a provisionné 7 milliards de plus pour les paiements futurs.

Les Echos

» More environmental impacts by Wyeth
» Pollutions in 2007

year

country : consequences

source

2 informations, access to subscribers

» More environmental impacts by Wyeth
» Pollutions in 2007

Financials (8)

Lobbying & corruption (6)

Subsidy

Advertising & marketing (6)

year

financial misdemeanor

sales

income

source

2005

Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said.

Canadian Press

2004

1,23

billion US$

Les Echos

2002

14,58

4,45

billion US$

2002

Pratiques fiscales douteuses, déclarations mensongères aux auditeurs, utilisation frauduleuse des budgets marketing, inventaires gonflés, contrats avec des sociétés liées à certains dirigeants, primes déposées dans des comptes offshore…

New York Times

2001

14,13

2,29

billion US$

2000

13,26

-2,37

billion US$

1999

13,55

-1,23

billion US$

1998

13,46

2,47

billion US$

» More financial data for Wyeth
» Financial delinquency in 2007

year

financial misdemeanor

sales

income

assets

buyback

source

8 informations, access to subscribers

» More financial data for Wyeth
» Financial delinquency in 2007

year

purpose : intermediary/lobby : institution

source

2001

Access to foreign market (through MAI, WTO, GATS), prevent binding environmental regulations : USCIB (US Council For International Business) : : US Government

translate

USCIB

2000

Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate

translate

Washington Post

2000

Investment protection and market access (to Mexico and Canada through NAFTA), to Latin America (through FTAA). : Business Roundtable : : US government, senate, congress

translate

Center for Responsive Politics

1998

Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 52 thousand US$ : US President, Congress, Senate

translate

Center for Responsive Politics

1997

Legislation favorable to company's interests : Direct donation : amount: 103 thousand US$ : US President, Congress, Senate

translate

Center for Responsive Politics

1997

Legislation favorable to company's interests : Direct donation : amount: 2500 thousand US$ : US President, Congress, Senate

translate

Center for Responsive Politics

» More influence from Wyeth
» Influence in 2007

year

purpose : intermediary/lobby : institution

source

6 informations, access to subscribers

» More influence from Wyeth
» Influence in 2007

year

dubious practice : image

source

2008

Disinformation: According to internal documents, the pharmaceutical company Wyeth "paid ghostwriters to produce medical journal articles favorable to its female hormone replacement therapy Prempro." As early as 1997, Wyeth paid the "medical writing firm" DesignWrite to publish favorable journal articles about Prempro under academics' names. "Company executives came up with ideas" for the articles, "titled them, drafted outlines, paid writers to draft the manuscripts, recruited academic authors and identified publications to run the articles -- all without disclosing the companies' roles to journal editors or readers.:

New York Times

2007

Disinformation: In early September, "major newspapers reported the alarming news that suicides among young people were on the rise because of a precipitous drop in the use of antidepressants," writes Alison Bass. The academic study the news articles were based on concluded that new safety warnings for young people using antidepressant drugs had discouraged doctors from writing prescriptions for depressed youths. But there's a hole in that argument: "while there was indeed an upturn in suicide rates among youths ... the number of prescriptions for antidepressants in the same age group remained basically unchanged." Bass points out that the pharmaceutical companies that make antidepressants might "benefit from the latest alarm about an apparent upturn in youth suicide rates. ... These companies have an enormous stake in reversing the current FDA warnings." Pfizer, which makes the antidepressant Zoloft, did provide $30,000 for the academic study, and the study's lead authors have ties to Pfizer, GlaxoSmithKline and Wyeth Pharmaceuticals. "This isn't the first time that suicide rates have been trotted out as a public relations weapon," Bass adds. "Proponents of psychotropic drugs have long argued that suicide rates ... fell after" such drugs were introduced, though the decline began well before the drugs were widely prescribed.:

Boston Globe

2001

ad budget: 400 million US$;

Advertising Age

2000

ad budget: 445 million US$;

Advertising Age

1998

ad budget: 428 million US$;

Advertising Age

1997

ad budget: 443 million US$;